Teva Provides Update on Generic Prevacid(R) Litigation

JERUSALEM--(Business Wire)--
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today
that the U.S. District Court for the District of Delaware has issued a
decision in its litigation over the Company's Abbreviated New Drug
Application (ANDA) to market its generic version of TAP Pharmaceutical
Products Inc.'s Prevacid(R) (Lansoprazole) Delayed Release Capsules,
15 mg and 30 mg., holding that U.S. Patent No. 4,628,098 is valid and
enforceable. Teva plans to appeal this decision.

About Teva

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is
among the top 20 pharmaceutical companies in the world and is the
world's leading generic pharmaceutical company. The Company develops,
manufactures and markets generic and innovative human pharmaceuticals
and active pharmaceutical ingredients, as well as animal health
pharmaceutical products. Over 80 percent of Teva's sales are in North
America and Europe.

Safe Harbor Statement under the U. S. Private Securities
Litigation Reform Act of 1995:

This release contains forward-looking statements, which express
the current beliefs and expectations of management. Such statements
are based on management's current beliefs and expectations and involve
a number of known and unknown risks and uncertainties that could cause
Teva's future results, performance or achievements to differ
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Important factors that
could cause or contribute to such differences include risks relating
to: Teva's ability to accurately predict future market conditions,
potential liability for sales of generic products prior to a final
resolution of outstanding patent litigation, including that relating
to the generic versions of Allegra(R), Neurontin(R), Lotrel(R),
Famvir(R) and Protonix(R), Teva's ability to successfully develop and
commercialize additional pharmaceutical products, the introduction of
competing generic equivalents, the extent to which Teva may obtain
U.S. market exclusivity for certain of its new generic products and
regulatory changes that may prevent Teva from utilizing exclusivity
periods, competition from brand-name companies that are under
increased pressure to counter generic products, or competitors that
seek to delay the introduction of generic products, the impact of
consolidation of our distributors and customers, the effects of
competition on our innovative products, especially Copaxone(R) sales,
the impact of pharmaceutical industry regulation and pending
legislation that could affect the pharmaceutical industry, the
difficulty of predicting U.S. Food and Drug Administration, European
Medicines Agency and other regulatory authority approvals, the
regulatory environment and changes in the health policies and
structures of various countries, our ability to achieve expected
results though our innovative R&D efforts, Teva's ability to
successfully identify, consummate and integrate acquisitions,
potential exposure to product liability claims to the extent not
covered by insurance, dependence on the effectiveness of our patents
and other protections for innovative products, significant operations
worldwide that may be adversely affected by terrorism, political or
economical instability or major hostilities, supply interruptions or
delays that could result from the complex manufacturing of our
products and our global supply chain, environmental risks,
fluctuations in currency, exchange and interest rates, and other
factors that are discussed in Teva's Annual Report on Form 20-F and
its other filings with the U.S. Securities and Exchange Commission.
Forward-looking statements speak only as of the date on which they are
made and the Company undertakes no obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise.

Teva Pharmaceutical Industries Ltd.
Elana Holzman, 972 (3) 926-7554
or
Teva North America
Kevin Mannix, 215-591-8912
www.tevapharm.com

Copyright Business Wire 2008